-
Nature Biomedical Engineering: The Wuhan University team developed nano hydrogels to regulate oral microbes and enhance the effect of PD-1 therapy
Time of Update: 2021-12-04
Based on the above findings, the research team hopes to develop a strategy to regulate the oral microbiota to activate the anti-cancer immune response, thereby helping the treatment of patients with oral squamous cell carcinoma .
-
Eur J Cancer: The effect of DNA damage repair status on the activity of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
Time of Update: 2021-12-04
Previous studies have shown that Cabazitaxel can improve the overall survival (OS) of patients with metastatic castration-resistant prostate cancer (mCRPC) after treatment failure with abiraterone/enzalutamide and docetaxel, although The benefits of the presence of DNA damage repair (DDR) defects are unclear .
-
Aliment Pharmacol Ther: Serum GDF15 can predict the risk of liver cancer after hepatitis C virus is eliminated
Time of Update: 2021-12-04
The GDF15, AFP and FIB-4 index scores can predict the risk of liver cancer after hepatitis C is cured .
The GDF15, AFP and FIB-4 index scores can predict the risk of liver cancer after hepatitis C is cured .
-
ESMO Open: A first-line regimen of paclitaxel combined with carboplatin plus bevacizumab for the treatment of recurrent/metastatic nasopharyngeal carcinoma
Time of Update: 2021-12-04
In the first-line regimen of paclitaxel combined with carboplatin, the addition of bevacizumab cannot prolong the progression-free survival and overall survival of patients with recurrent or metastatic nasopharyngeal carcinoma, but it can increase the tumor shrinkage rate .
-
Bispecific cancer immunotherapy!
Time of Update: 2021-12-04
Recommended reading: ASH 2020: Regeneron CD20/CD3 double antibody shows positive clinical data, with CAR-T cells as a potential competitor Yimai Meng broke the news on June 10, 2020, AbbVie and Genmab announced Reached a cooperation to jointly develop Genmab’s three next-generation bispecific antibody products, including CD3/CD20 bi-antibody epcoritamab (currently undergoing clinical trials for B-cell non-Hodgkin’s lymphoma).
-
Front Oncol: Based on the SEER database to compare the survival results of radical prostatectomy (PR) and radiotherapy (RT) for metastatic prostate cancer
Time of Update: 2021-12-04
In the unmatched cohort, the Cox proportional hazards model showed no significant difference between the two groups of CSM or ACM (CSM: HR = 0.
statistics Prognostic analysis Prognostic analysisThe Kaplan-Meier survival curve showed that the 10-year survival rates of the RP and RT groups before PSM were 70.
-
Clin Cancer Res: base excision repair inhibitor TRC102 combined with pemetrexed-cisplatin-radiotherapy standard regimen for the treatment of advanced non-squamous non-small cell lung cancer
Time of Update: 2021-12-04
This is a phase I clinical trial that evaluated the optimal dose, efficacy and safety of pemetrexed and TRC102 combined with cisplatin radiotherapy in the treatment of stage III non-squamous non-small cell lung cancer (NS-NSCLC) .
-
Nature: The fatty acids in this widely consumed vegetable oil will promote cancer metastasis
Time of Update: 2021-12-04
Based on this discovery, the research team has developed a therapy to block cancer cell metastasis, and is expected to launch human clinical trials in the next few years .
-
Blood: Incidence of clonal hematopoiesis in older people ≥80
Time of Update: 2021-12-04
All in all, specific mutation patterns can stratify the risk of myeloid tumors and inflammation-related diseases in people over 80 years of age .
Specific mutation patterns can stratify the risk of myeloid tumors and inflammation-related diseases in people over 80 years old.
-
Cancer Cell The determinants of whether patients with renal clear cell carcinoma respond to anti-PD-1
Time of Update: 2021-12-04
TCR analysis revealed that responders had a higher number of amplified TCR clones before treatment, indicating the occurrence of an immune response .
Differential gene expression analysis showed that nivolumab treatment increased T cell infiltration in both responders and non-responders.
-
Nature's heavyweight: CAR-T treatment of solid tumors welcomes a major breakthrough, a new generation of therapy may become a cancer killer
Time of Update: 2021-12-04
surface peptides, and can be used for children " of peptide-center " chimeric antigen receptor ( "peptide-centric" antigen chimeric receptors , the PC-the CAR for targeted), this new type of CAR-T cells capable of stimulating an immune reaction , And after testing in mice, it showed the therapeutic effect of complete tumor regression .
-
Clin Cancer Res: Efficacy, safety and biomarkers of torepalizumab in second-line treatment of metastatic urothelial cancer
Time of Update: 2021-12-04
Progression-free survival rate of PD-L1 positive or negative patientsProgression-free survival rate of PD-L1 positive or negative patientsThe objective response rate of patients with PD-L1 positive and high TMB value (≥10 mutations/Mb) was significantly higher than that of PD-L1 negative patients (42% vs 17%; p=0.
-
Clinical Nutrition: Skeletal muscle density and visceral adipose tissue index are associated with the survival rate of renal cell carcinoma
Time of Update: 2021-12-04
statistics This study confirms that higher SMD and higher VATI are associated with better survival rates for RCC patients and may contribute to a better prognosis .
This study confirms that higher SMD and higher VATI are associated with better survival rates for RCC patients and may contribute to a better prognosis .
-
JCO: Quality of life for prostate cancer patients treated with docetaxel vs. abiraterone
Time of Update: 2021-12-04
Compared with docetaxel + standard androgen deprivation therapy, patients with locally advanced or metastatic hormone-sensitive prostate cancer treated with abiraterone acetate combined with prednisone or prednisone + standard androgen deprivation therapy within two years Reported quality of life is better.
-
Nature Communications: PD-1/CD137 dual antibody has excellent effect and good safety
Time of Update: 2021-12-04
Recently, Cinda Bio's research team published a research paper titled Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity in Nature Communications .
-
NEJM: Belzutifan is effective in treating VHL-related tumors
Time of Update: 2021-12-04
HIF-2α inhibitors have a good therapeutic effect on patients with Heber-Lindau syndrome-related tumors, and the adverse events are mostly grade 1-2 events .
HIF-2α inhibitors have a good therapeutic effect on patients with Heber-Lindau syndrome-related tumors, and the adverse events are mostly grade 1-2 events .
-
Nature Nanotechnology: I was stunned. Cancer cells learned 36 tricks. They took money from the bottom and stole the mitochondria of immune cells to achieve immune escape.
Time of Update: 2021-12-04
Faced with the suppression of the firepower of the immune system, will cancer cells evolve a mechanism to weaken them and then outwit the immune system?In this study, the research team first noticed mitochondrial transfer, an easily overlooked intercellular communication phenomenon .
-
The first-line all-population indication of Odivo® for advanced gastric cancer is grandly launched, fully benefiting and opening up a new "stomach"
Time of Update: 2021-12-04
Therapy, but it has not been possible; until August this year, with the results of the landmark study CheckMate-649, China’s first immunotherapy Odivo (Navuliumab) was approved for the first-line treatment of advanced gastric cancer in combination with chemotherapy, and Regardless of the expression of PD-L1, the bottleneck of first-line treatment that has been silent for many years finally ushered in a breakthrough, bringing the dawn of life to many Chinese patients .
-
JAHA: Clinical progress of carcinoid heart disease
Time of Update: 2021-12-04
Recently, the heart blood vessels published a research article on the disease areas authoritative magazine JAHA, this study aimed to assess the prevalence and natural history of CaHD by annual echocardiography .
-
CA (IF=509) System introduction of radiotherapy and improved technology in clinical application (worthy of collection)
Time of Update: 2021-12-04
Hall team from the Medical College of Wisconsin published an online review titled "Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians" in CA: A Cancer Journal for Clinicians (IF=509) The article, this review provides clinicians with an overview, describing the process of ART, especially MRgART .
